To prepare APOE and TREM2 ASO efficacy studies in disease-relevant mouse models of Alzheimer’s disease, we explored if ASOs can also target disease-relevant genes in human microglia in vivo. This evidence concerns the gene TREM2 and early-onset autosomal dominant Alzheimer disease.